Literature DB >> 16890837

The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

Charles F Gilks1, Siobhan Crowley, René Ekpini, Sandy Gove, Jos Perriens, Yves Souteyrand, Don Sutherland, Marco Vitoria, Teguest Guerma, Kevin De Cock.   

Abstract

WHO has proposed a public-health approach to antiretroviral therapy (ART) to enable scaling-up access to treatment for HIV-positive people in developing countries, recognising that the western model of specialist physician management and advanced laboratory monitoring is not feasible in resource-poor settings. In this approach, standardised simplified treatment protocols and decentralised service delivery enable treatment to be delivered to large numbers of HIV-positive adults and children through the public and private sector. Simplified tools and approaches to clinical decision-making, centred on the "four Ss"--when to: start drug treatment; substitute for toxicity; switch after treatment failure; and stop--enable lower level health-care workers to deliver care. Simple limited formularies have driven large-scale production of fixed-dose combinations for first-line treatment for adults and lowered prices, but to ensure access to ART in the poorest countries, the care and drugs should be given free at point of service delivery. Population-based surveillance for acquired and transmitted resistance is needed to address concerns that switching regimens on the basis of clinical criteria for failure alone could lead to widespread emergence of drug-resistant virus strains. The integrated management of adult or childhood illness (IMAI/IMCI) facilitates decentralised implementation that is integrated within existing health systems. Simplified operational guidelines, tools, and training materials enable clinical teams in primary-care and second-level facilities to deliver HIV prevention, HIV care, and ART, and to use a standardised patient-tracking system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16890837     DOI: 10.1016/S0140-6736(06)69158-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  260 in total

1.  Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.

Authors:  C Kityo; A S Walker; L Dickinson; F Lutwama; J Kayiwa; F Ssali; R Nalumenya; D Tumukunde; P Munderi; A Reid; C F Gilks; D M Gibb; S Khoo
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

2.  Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.

Authors:  Patrice Severe; Marc Antoine Jean Juste; Alex Ambroise; Ludger Eliacin; Claudel Marchand; Sandra Apollon; Alison Edwards; Heejung Bang; Janet Nicotera; Catherine Godfrey; Roy M Gulick; Warren D Johnson; Jean William Pape; Daniel W Fitzgerald
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance.

Authors:  Robert J Gifford; Soo-Yon Rhee; Nicolas Eriksson; Tommy F Liu; Mark Kiuchi; Amar K Das; Robert W Shafer
Journal:  AIDS       Date:  2008-03-30       Impact factor: 4.177

4.  Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.

Authors:  Alana T Brennan; Kate Shearer; Mhairi Maskew; Lawrence Long; Ian Sanne; Matthew P Fox
Journal:  Trop Med Int Health       Date:  2014-03-03       Impact factor: 2.622

5.  A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.

Authors:  Nittaya Phanuphak; Jintanat Ananworanich; Nipat Teeratakulpisarn; Tanate Jadwattanakul; Stephen J Kerr; Nitiya Chomchey; Piranun Hongchookiat; Pornpen Mathajittiphun; Suteeraporn Pinyakorn; Patcharawee Rungrojrat; Pairoa Praihirunyakit; Mariana Gerschenson; Praphan Phanuphak; Victor Valcour; Jerome H Kim; Cecilia Shikuma
Journal:  Antivir Ther       Date:  2012-12-07

6.  The human immunodeficiency virus and the cardiometabolic syndrome in the developing world: an African perspective.

Authors:  Eugene Mutimura; Nigel J Crowther; Aimee Stewart; W Todd Cade
Journal:  J Cardiometab Syndr       Date:  2008

7.  Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults.

Authors:  Eugène Messou; Delphine Gabillard; Raoul Moh; André Inwoley; Souleymane Sorho; Serge Eholié; François Rouet; Catherine Seyler; Christine Danel; Xavier Anglaret
Journal:  Bull World Health Organ       Date:  2008-06       Impact factor: 9.408

8.  Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.

Authors:  Damalie Nakanjako; Agnes N Kiragga; Beverly S Musick; Constantin T Yiannoutsos; Kara Wools-Kaloustian; Lameck Diero; Patrick Oyaro; Emanuel Lugina; John C Ssali; Andrew Kambugu; Philippa Easterbrook
Journal:  AIDS       Date:  2016-07-31       Impact factor: 4.177

9.  Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD).

Authors:  J Zhou; P C K Li; N Kumarasamy; M Boyd; Y M A Chen; T Sirisanthana; S Sungkanuparph; S Oka; G Tau; P Phanuphak; V Saphonn; F J Zhang; S F S Omar; C K C Lee; R Ditangco; T P Merati; P L Lim; J Y Choi; M G Law; S Pujari
Journal:  HIV Med       Date:  2009-07-06       Impact factor: 3.180

Review 10.  Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Authors:  Lawrence Mbuagbaw; Sara Mursleen; James H Irlam; Alicen B Spaulding; George W Rutherford; Nandi Siegfried
Journal:  Cochrane Database Syst Rev       Date:  2016-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.